Galectin Therapeutics

About Galectin Therapeutics

Galectin Therapeutics is a biotechnology company focused on developing novel therapies to improve the lives of patients with chronic liver disease, such as MASH cirrhosis, and cancer. Their mission is to address unmet medical needs in these areas through innovative treatments.

Products & Services

Belapectin (GR-MD-02):A carbohydrate-based drug that inhibits the galectin-3 protein, which is involved in inflammatory, fibrotic, and malignant diseases. It is being developed for conditions like MASH cirrhosis and cancer immunotherapy.

NAVIGATE Study:A clinical study focused on MASH cirrhosis, aimed at evaluating potential treatments for this life-threatening condition with no current cure.

Specialties

Galectin-3 inhibitors Chronic liver disease treatment Cancer immunotherapy MASH cirrhosis research Fibrosis treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 10000000 MR: - FA: $10 million FAN: 10000000	D: 2025-07-09 FD: 2025-07-09	1 investors

Debt Latest

2025-07-09

$10.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richard E. Uihlein

Chairman of the Board

J

Joel Lewis

Chief Executive Officer (CEO) and President

G

Gilbert F. Amelio

Independent Director

B

Benjamin S. Carson

Independent Director

K

Kary Eldred

Independent Director

K

Kevin D. Freeman

Vice Chairman of the Board

View 17 more team members with Pro

Unlock Full Team Directory

Recent News